# Drug Interaction Study With a Potential Alzheimer's Disease Compound

> **NCT00726726** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 22 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)
- **DRUG:** BMS-708163
- **DRUG:** BMS-708163 + Cooperstown Cocktail

## Key facts

- **NCT ID:** NCT00726726
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2008-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00726726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00726726, "Drug Interaction Study With a Potential Alzheimer's Disease Compound". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00726726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*